vs
Side-by-side financial comparison of Bioventus Inc. (BVS) and SILICON LABORATORIES INC. (SLAB). Click either name above to swap in a different company.
SILICON LABORATORIES INC. is the larger business by last-quarter revenue ($208.2M vs $157.9M, roughly 1.3× Bioventus Inc.). On growth, SILICON LABORATORIES INC. posted the faster year-over-year revenue change (25.2% vs 2.8%). Bioventus Inc. produced more free cash flow last quarter ($37.4M vs $-1.6M). Over the past eight quarters, SILICON LABORATORIES INC.'s revenue compounded faster (39.9% CAGR vs 10.4%).
Bioventus Inc. is a global medical technology company specializing in orthobiologic solutions. It develops and commercializes products supporting bone and joint healing, musculoskeletal pain management, and regenerative care for patients. Its offerings serve orthopedic clinicians, physical therapists, and patients across North America, Europe, and Asia Pacific, with core segments covering surgical orthobiologics and non-surgical pain relief solutions.
Silicon Laboratories, Inc., commonly referred to as Silicon Labs, is a fabless global technology company that designs and manufactures semiconductors, other silicon devices and software, which it sells to electronics design engineers and manufacturers in Internet of Things (IoT) infrastructure worldwide.
BVS vs SLAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $157.9M | $208.2M |
| Net Profit | $14.8M | — |
| Gross Margin | 68.9% | 63.4% |
| Operating Margin | 12.3% | -1.6% |
| Net Margin | 9.3% | — |
| Revenue YoY | 2.8% | 25.2% |
| Net Profit YoY | 3902.8% | — |
| EPS (diluted) | $0.21 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $208.2M | ||
| Q4 25 | $157.9M | $206.0M | ||
| Q3 25 | $138.7M | $192.8M | ||
| Q2 25 | $147.7M | $177.7M | ||
| Q1 25 | $123.9M | — | ||
| Q4 24 | $153.6M | $166.2M | ||
| Q3 24 | $139.0M | $166.4M | ||
| Q2 24 | $151.2M | $145.4M |
| Q1 26 | — | — | ||
| Q4 25 | $14.8M | $-9.9M | ||
| Q3 25 | $3.2M | $-21.8M | ||
| Q2 25 | $7.5M | — | ||
| Q1 25 | $-2.6M | — | ||
| Q4 24 | $-388.0K | — | ||
| Q3 24 | $-5.2M | $-28.5M | ||
| Q2 24 | $-25.7M | $-82.2M |
| Q1 26 | — | 63.4% | ||
| Q4 25 | 68.9% | 57.8% | ||
| Q3 25 | 68.0% | 56.1% | ||
| Q2 25 | 69.1% | 55.0% | ||
| Q1 25 | 67.0% | — | ||
| Q4 24 | 66.8% | 54.3% | ||
| Q3 24 | 67.3% | 54.3% | ||
| Q2 24 | 68.5% | 52.7% |
| Q1 26 | — | -1.6% | ||
| Q4 25 | 12.3% | -6.0% | ||
| Q3 25 | 8.1% | -11.9% | ||
| Q2 25 | 12.4% | -18.1% | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | 5.0% | -17.2% | ||
| Q3 24 | 2.6% | -17.9% | ||
| Q2 24 | -20.8% | -33.0% |
| Q1 26 | — | — | ||
| Q4 25 | 9.3% | -4.8% | ||
| Q3 25 | 2.3% | -11.3% | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | -2.1% | — | ||
| Q4 24 | -0.3% | — | ||
| Q3 24 | -3.7% | -17.1% | ||
| Q2 24 | -17.0% | -56.5% |
| Q1 26 | — | $-0.07 | ||
| Q4 25 | $0.21 | $-0.30 | ||
| Q3 25 | $0.05 | $-0.67 | ||
| Q2 25 | $0.11 | $-0.94 | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $0.00 | $-0.72 | ||
| Q3 24 | $-0.08 | $-0.88 | ||
| Q2 24 | $-0.40 | $-2.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $51.2M | $443.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $184.1M | $1.1B |
| Total Assets | $683.6M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $443.6M | ||
| Q4 25 | $51.2M | $439.0M | ||
| Q3 25 | $42.2M | $415.5M | ||
| Q2 25 | $32.9M | $424.8M | ||
| Q1 25 | $22.8M | — | ||
| Q4 24 | $41.6M | $382.2M | ||
| Q3 24 | $43.1M | $369.7M | ||
| Q2 24 | $32.0M | $339.2M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $184.1M | $1.1B | ||
| Q3 25 | $166.1M | $1.1B | ||
| Q2 25 | $161.2M | $1.1B | ||
| Q1 25 | $148.1M | — | ||
| Q4 24 | $147.9M | $1.1B | ||
| Q3 24 | $148.7M | $1.1B | ||
| Q2 24 | $150.9M | $1.1B |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $683.6M | $1.3B | ||
| Q3 25 | $701.6M | $1.2B | ||
| Q2 25 | $706.8M | $1.2B | ||
| Q1 25 | $691.4M | — | ||
| Q4 24 | $728.0M | $1.2B | ||
| Q3 24 | $769.5M | $1.2B | ||
| Q2 24 | $792.2M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $38.0M | $8.3M |
| Free Cash FlowOCF − Capex | $37.4M | $-1.6M |
| FCF MarginFCF / Revenue | 23.7% | -0.8% |
| Capex IntensityCapex / Revenue | 0.4% | 4.8% |
| Cash ConversionOCF / Net Profit | 2.57× | — |
| TTM Free Cash FlowTrailing 4 quarters | $72.1M | $65.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $8.3M | ||
| Q4 25 | $38.0M | $34.3M | ||
| Q3 25 | $30.1M | $4.9M | ||
| Q2 25 | $25.9M | $48.1M | ||
| Q1 25 | $-19.3M | — | ||
| Q4 24 | $19.3M | $10.1M | ||
| Q3 24 | $10.3M | $31.6M | ||
| Q2 24 | $15.2M | $16.1M |
| Q1 26 | — | $-1.6M | ||
| Q4 25 | $37.4M | $27.9M | ||
| Q3 25 | $29.6M | $-3.8M | ||
| Q2 25 | $25.3M | $43.3M | ||
| Q1 25 | $-20.2M | — | ||
| Q4 24 | $18.7M | $6.2M | ||
| Q3 24 | $10.3M | $29.4M | ||
| Q2 24 | $15.1M | $12.6M |
| Q1 26 | — | -0.8% | ||
| Q4 25 | 23.7% | 13.6% | ||
| Q3 25 | 21.4% | -2.0% | ||
| Q2 25 | 17.1% | 24.4% | ||
| Q1 25 | -16.3% | — | ||
| Q4 24 | 12.2% | 3.7% | ||
| Q3 24 | 7.4% | 17.7% | ||
| Q2 24 | 10.0% | 8.7% |
| Q1 26 | — | 4.8% | ||
| Q4 25 | 0.4% | 3.1% | ||
| Q3 25 | 0.3% | 4.5% | ||
| Q2 25 | 0.5% | 2.7% | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 0.4% | 2.4% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.1% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.57× | — | ||
| Q3 25 | 9.54× | — | ||
| Q2 25 | 3.48× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BVS
| Pain Treatments | $71.1M | 45% |
| Surgical Solutions | $48.9M | 31% |
| Restorative Therapies | $19.5M | 12% |
| Other | $18.4M | 12% |
SLAB
| Sales Channel Through Intermediary | $157.5M | 76% |
| Sales Channel Directly To Consumer | $50.7M | 24% |
